limited scleroderma

Summary

Summary: The least progressive form of SYSTEMIC SCLERODERMA with skin thickening restricted to the FACE; NECK; and areas distal to the elbows and/or knees, sparing the trunk. The CREST SYNDROME is a form of limited scleroderma.

Top Publications

  1. ncbi Association of increased telomere lengths in limited scleroderma, with a lack of age-related telomere erosion
    A MacIntyre
    Division of Cancer Sciences and Molecular Pathology, University of Glasgow, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
    Ann Rheum Dis 67:1780-2. 2008
  2. pmc Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database
    U A Walker
    Department of Rheumatology, Basle University, Felix Platter Spital, Burgfelderstrasse 101, Basel 4012, Switzerland
    Ann Rheum Dis 66:754-63. 2007
  3. ncbi Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival
    Aryeh Fischer
    Autoimmune Lung Disease Center, Department of Medicine, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
    Chest 134:601-5. 2008
  4. ncbi Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis
    Gian Paolo Bezante
    Division of Cardiology, Department of Internal Medicine, University of Genoa, Genoa, Italy
    J Rheumatol 34:2431-7. 2007
  5. ncbi Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody
    Achini Perera
    University of Pittsburgh School of Medicine, 3500 Terrace Street, Pittsburgh, PA 15261, USA
    Arthritis Rheum 56:2740-6. 2007
  6. pmc Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma
    A C Gelber
    Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Building Center Tower, Suite 4100, Room 407, Baltimore MD 21224, USA
    Ann Rheum Dis 65:1028-32. 2006
  7. ncbi Lack of increased expression of cell surface markers for circulating fibrocyte progenitors in limited scleroderma
    R Russo
    Department of Rheumatology, Westmead Hospital, Corner of Hawkesbury and Darcy Road, Westmead, New South Wales 2145, Australia
    Clin Rheumatol 26:1136-41. 2007
  8. ncbi Effectiveness of a treatment based on melatonin in five patients with systemic sclerosis
    Mauro Todisco
    ASL 11 Local Health Department of National Health Service, Fermo, Italy
    Am J Ther 13:84-7. 2006
  9. ncbi Distinct expression of adhesion molecules on skin fibroblasts from patients with diffuse and limited systemic sclerosis. A pilot study
    Florenzo Iannone
    Rheumatology Unit DIMIMP, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
    J Rheumatol 32:1893-8. 2005
  10. ncbi The use of the hand anatomic index to assess deformity and impaired function in systemic sclerosis
    A J Roberts-Thomson
    University of South Australia, Daw Park, South Australia, Australia
    Rheumatol Int 26:439-44. 2006

Research Grants

Detail Information

Publications160 found, 100 shown here

  1. ncbi Association of increased telomere lengths in limited scleroderma, with a lack of age-related telomere erosion
    A MacIntyre
    Division of Cancer Sciences and Molecular Pathology, University of Glasgow, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
    Ann Rheum Dis 67:1780-2. 2008
    ..We aimed to assess if telomere biology was abnormal in a cohort of patients with limited cutaneous systemic sclerosis (lcSSc)...
  2. pmc Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database
    U A Walker
    Department of Rheumatology, Basle University, Felix Platter Spital, Burgfelderstrasse 101, Basel 4012, Switzerland
    Ann Rheum Dis 66:754-63. 2007
    ..In order to better understand the vascular, immunological and fibrotic processes of SSc and to guide its treatment, the EULAR Scleroderma Trials And Research (EUSTAR) group was formed in June 2004...
  3. ncbi Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival
    Aryeh Fischer
    Autoimmune Lung Disease Center, Department of Medicine, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
    Chest 134:601-5. 2008
    ..To evaluate the pathologic patterns, clinical features, and survival among subjects with scleroderma (ie, systemic sclerosis [SSc]) and clinically significant interstitial lung disease (ILD) evaluated at an ILD center...
  4. ncbi Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis
    Gian Paolo Bezante
    Division of Cardiology, Department of Internal Medicine, University of Genoa, Genoa, Italy
    J Rheumatol 34:2431-7. 2007
    ..To assess myocardial involvement in patients with systemic sclerosis (SSc) with no signs or symptoms of cardiac impairment (New York Heart Association functional class I)...
  5. ncbi Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody
    Achini Perera
    University of Pittsburgh School of Medicine, 3500 Terrace Street, Pittsburgh, PA 15261, USA
    Arthritis Rheum 56:2740-6. 2007
    ....
  6. pmc Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma
    A C Gelber
    Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Building Center Tower, Suite 4100, Room 407, Baltimore MD 21224, USA
    Ann Rheum Dis 65:1028-32. 2006
    ..It is not known whether distinct centromere proteins (CENP) are targeted in primary Sjögren's syndrome (pSS) and scleroderma...
  7. ncbi Lack of increased expression of cell surface markers for circulating fibrocyte progenitors in limited scleroderma
    R Russo
    Department of Rheumatology, Westmead Hospital, Corner of Hawkesbury and Darcy Road, Westmead, New South Wales 2145, Australia
    Clin Rheumatol 26:1136-41. 2007
    ..in the cell surface characteristics of circulating fibrocyte progenitors (monocytes) in patients with limited scleroderma compared to controls...
  8. ncbi Effectiveness of a treatment based on melatonin in five patients with systemic sclerosis
    Mauro Todisco
    ASL 11 Local Health Department of National Health Service, Fermo, Italy
    Am J Ther 13:84-7. 2006
    ..6 months; range, 7-44 months). Toxicity was lacking, with the only side effect being drowsiness. Our experience suggests that the combination of melatonin-ACTH-vitamin E may be safe and effective in patients with SSc...
  9. ncbi Distinct expression of adhesion molecules on skin fibroblasts from patients with diffuse and limited systemic sclerosis. A pilot study
    Florenzo Iannone
    Rheumatology Unit DIMIMP, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
    J Rheumatol 32:1893-8. 2005
    ..We investigated the expression of integrins and CD44 on skin fibroblasts from patients with limited and diffuse SSc...
  10. ncbi The use of the hand anatomic index to assess deformity and impaired function in systemic sclerosis
    A J Roberts-Thomson
    University of South Australia, Daw Park, South Australia, Australia
    Rheumatol Int 26:439-44. 2006
    ..patients with increasing hand deformity and separated patients with diffuse scleroderma (n=12) from limited scleroderma (n=18), P=0.005...
  11. ncbi Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?
    M T Carulli
    Centre for Rheumatology, Royal Free and University College Medical School, Rowland Hill Street, Hampstead, London, NW3 2PF, UK
    Ann Rheum Dis 67:105-9. 2008
    ..To explore the potential value of serum CCL2 measurement in disease assessment, we have compared CCL2 levels with clinical phenotype and investigated effect of therapy on circulating CCL2...
  12. ncbi High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease
    Jonathan G Goldin
    David Geffen School of Medicine at UCLA, Department of Radiology, Los Angeles, CA 90095 1721, USA
    Chest 134:358-67. 2008
    ..The frequency, nature, and progression of interstitial lung disease seen on high-resolution CT (HRCT) scans in patients with diffuse SSc (dcSSc) compared with those with limited SSc (lcSSc) has not been well characterized...
  13. ncbi N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma
    M Dziadzio
    Centre for Rheumatology, Royal Free Hospital and University College School of Medicine, Pond Street, London, UK
    QJM 98:485-92. 2005
    ..Elevated production of CTGF might be responsible for maintenance of the fibrotic phenotype in scleroderma. Assays of CTGF or of its fragments are potential non-invasive measures of the fibrotic response in scleroderma...
  14. ncbi Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury
    N Assous
    Department of Rheumatology A, Paris 5 University, Assistance Publique Hopitaux de Paris, Cochin Hospital, Paris, France
    Clin Exp Rheumatol 23:199-204. 2005
    ..To investigate the prevalence and clinical significance of antiphospholipid antibodies in patients with systemic sclerosis (SSc)...
  15. ncbi Classification of systemic sclerosis. Visions and reality
    F A Wollheim
    Department of Rheumatology, Lund University Hospital, S 21774 Lund, Sweden
    Rheumatology (Oxford) 44:1212-6. 2005
    ..There is no convincing evidence of any advantage for distinguishing the limited, intermediate and diffuse forms of SSc rather than only the limited and diffuse forms...
  16. ncbi Differential expression of tissue kallikrein in the skin of systemic sclerosis
    A F Milia
    Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy
    Histol Histopathol 20:415-22. 2005
    ..The decreased expression of t-kallikrein may be involved in the impairment of the sweating process, vessel functionality and angiogenesis...
  17. pmc Alpha4beta1 and alpha4beta7 CD4 T cell numbers increase and CLA CD4 T cell numbers decrease in systemic sclerosis
    E Scala
    Istituto Dermopatico dell Immacolata, Istituto di Ricovero e Cura a Carattere Scientifico IDI IRCCS, Rome, Italy
    Clin Exp Immunol 139:551-7. 2005
    ....
  18. ncbi Clonal T cells in the blood of patients with systemic sclerosis
    Isabelle Marie
    Department of Internal Medicine and INSERM Unit 644, Centre Hospitalier Universitaire de Rouen Boisguillaume, Rouen, France
    Arch Dermatol 141:88-9. 2005
    ..It has been suggested that clonal T cells may play a critical role in the pathogenesis of systemic sclerosis...
  19. ncbi Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma
    A L Lagan
    Clinical Genomics Group, National Heart and Lung Institute and Royal Brompton Hospital, Imperial College, 1B Manresa Road, London SW3 6LR, UK
    Rheumatology (Oxford) 44:197-201. 2005
    ..We set out to reproduce and to positionally clone these disease associations in a set of UK Caucasian scleroderma patients and ethnically matched controls...
  20. ncbi Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study
    B Rozman
    University Medical Centre, Department of Rheumatology, Vodnikova 62, SI 1000 Ljubljana, Slovenia
    Ann Rheum Dis 67:1282-6. 2008
    ..To determine the prevalence of anti-Ku antibodies in 625 patients with systemic sclerosis (SSc) from six European rheumatological centres and to evaluate their clinical and serological characteristics...
  21. ncbi Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study
    Chris T Derk
    Department of Medicine, Division of Rheumatology, Thomas Jefferson University, Philadelphia, PA, 19017, USA
    Clin Rheumatol 25:831-4. 2006
    ..A higher clinical suspicion will lead to an earlier diagnosis and a potential decrease in morbidity and mortality...
  22. ncbi Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis
    Alfred Grassegger
    Dermatology, Phlebology and Laser Medicine, Salurner Strasse 15, Innsbruck, Austria
    Wien Med Wochenschr 158:19-28. 2008
    ..Anti-RNA polymerase I/III antibodies are associated with a high risk for renal involvement. Autoantibodies against the PDGF receptor and fibrillin-1 seem to play important roles in the pathogenetic process of systemic sclerosis...
  23. ncbi Nursing problems of patients with systemic sclerosis
    M Sierakowska
    Department of General Nursing, Medical University of Białystok, Poland
    Adv Med Sci 52:147-52. 2007
    ..The most characteristic form SSc is limited and diffuse systemic sclerosis. The SSc is characterized by the progressive fibrosis of the skin and internal organs, leading to their failure, morphology and blood vessels disorders...
  24. ncbi [Scleroderma]
    Françoise Bardet
    Krankenpfl Soins Infirm 100:55. 2007
  25. ncbi Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis
    Silvia Mattuzzi
    Dipartimento di Patologia, Universita di Verona, Verona, Italy
    J Rheumatol 34:997-1004. 2007
    ..To investigate possible associations of 9 single-nucleotide polymorphisms in the IL10, IL1B, IL1A, IL1RN, IL2, LTA, and IL6 genes with susceptibility to systemic sclerosis (SSc), and with clinical subtype of SSc patients...
  26. pmc Molecular subsets in the gene expression signatures of scleroderma skin
    Ausra Milano
    Department of Genetics, Dartmouth Medical School, Hanover, New Hampshire, United States of America
    PLoS ONE 3:e2696. 2008
    ..Scleroderma is a clinically heterogeneous disease with a complex phenotype. The disease is characterized by vascular dysfunction, tissue fibrosis, internal organ dysfunction, and immune dysfunction resulting in autoantibody production...
  27. pmc Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study
    F Nacci
    Department of Medicine and Surgery, University of Florence, Italy
    Ann Rheum Dis 66:977-9. 2007
    ..In systemic sclerosis (SSc), joint involvement may reduce the functional capacity of the hands. Intravenous immunoglobulins have previously been shown to benefit patients with SSc...
  28. ncbi Increased serum soluble CD40 levels in patients with systemic sclerosis
    Kazuhiro Komura
    Department of Dermatology, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan
    J Rheumatol 34:353-8. 2007
    ..To determine serum levels of soluble CD40 (sCD40) and clinical association in patients with systemic sclerosis (SSc)...
  29. ncbi Antifibrotic effects of hepatocyte growth factor on scleroderma fibroblasts and analysis of its mechanism
    Ryoko Sherriff-Tadano
    Graduate School of Medical Science, Saga Medical School, Saga, Japan
    Mod Rheumatol 16:364-71. 2006
    ..The present study indicates that HGF may be a promising therapeutic agent for this intractable disease...
  30. ncbi [Interstitial lung disease in systemic sclerosis]
    Luc Mouthon
    Service de Medecine Interne, Hopital Cochin, Centre de Référence pour les Vascularites et la Sclérodermie Systémique, AP HP, Paris
    Presse Med 35:1943-51. 2006
    ..A subgroup of patients with rapidly progressive ILD might benefit from intravenous cyclophosphamide pulses in association with 15 mg/d prednisone...
  31. ncbi Scleroderma in South Australia: further epidemiological observations supporting a stochastic explanation
    P J Roberts-Thomson
    Department of Immunology, Allergy and Arthritis, Flinders Medical Center, Adelaide, South Australia, Australia
    Intern Med J 36:489-97. 2006
    ..5-fold); however, the majority of the disease variance appears unexplained. A stochastic explanation based on genetic instability is favoured to explain this paradox...
  32. ncbi Functional hyperprolactinemia and hypophyseal microadenoma in systemic sclerosis
    Olga Vera-Lastra
    Department of Internal Medicine, Division of Research, Clinical and Epidemiology Research, Office of Education Research, Hospital de Espcialidades, Centro Medico La Raza, IMSS, Mexico City, Mexico
    J Rheumatol 33:1108-12. 2006
    ..We investigated the prevalence of prolactin (PRL)-secreting pituitary adenoma and evaluated production of PRL by dynamic testing with MTC in SSc...
  33. ncbi Proton magnetic resonance spectroscopy reveals central neuroaxonal impairment in systemic sclerosis
    Luca Bertinotti
    Department of Internal Medicine, Section of Pheumatology, AOUC, University of Florence, Italy
    J Rheumatol 33:546-51. 2006
    ..Involvement of the central nervous system (CNS) in systemic sclerosis (SSc) is rare. Proton magnetic resonance spectroscopy (1H-MRS) assesses in vivo cerebral metabolites. We investigated the biochemical modifications of the CNS in SSc...
  34. ncbi Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement
    I Moyssakis
    Laikon Hospital, Department of Cardiology, 17 Agiou Thomas Street, GR 15727 Goudi, Athens, Greece
    Rheumatology (Oxford) 44:251-4. 2005
    ..To study the stiffness of large arteries in relation to the extent of skin and lung fibrosis, aortic distensibility was examined in patients with diffuse and limited systemic sclerosis (SSc)...
  35. ncbi Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease
    Ronald J Oudiz
    Research and Education Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Chest 126:420-7. 2004
    ..To assess the efficacy and safety of continuous subcutaneous infusion of treprostinil, a stable prostacyclin analogue, for treating pulmonary arterial hypertension (PAH) in patients with connective tissue disease (CTD)...
  36. ncbi Parvoviral infection of endothelial cells and stromal fibroblasts: a possible pathogenetic role in scleroderma
    Cynthia M Magro
    Department of Pathology, The Ohio State University, Columbus, OH, USA
    J Cutan Pathol 31:43-50. 2004
    ..Having previously demonstrated parvovirus B19 (B19) DNA in bone marrow and skin biopsies of SSc patients in the absence of B19 viremia, we sought to further elucidate a role for B19 in the pathogenesis of SSc...
  37. ncbi Carotid and femoral arterial wall mechanics in scleroderma
    K S Cheng
    University Department of Surgery, University College London, London, UK
    Rheumatology (Oxford) 42:1299-305. 2003
    ....
  38. ncbi Delayed gastric emptying in patients with diffuse versus limited systemic sclerosis, unrelated to gastrointestinal symptoms and myoelectric gastric activity
    K Franck-Larsson
    Department of Medicine, Division of Rheumatology, University Hospital, Uppsala, Sweden
    Scand J Rheumatol 32:348-55. 2003
    ..To study the gastric function in patients with diffuse and limited systemic sclerosis (SSc) in relation to the degree of upper gastrointestinal symptoms...
  39. ncbi Analysis of the 5' flanking region of the interleukin 10 gene in patients with systemic sclerosis
    A Crilly
    Department of Medicine, Glasgow Royal Infirmary, Glasgow, UK
    Rheumatology (Oxford) 42:1295-8. 2003
    ..We postulated that there would be a difference in IL-10 polymorphisms in patients with limited (lSSc) and diffuse (dSSc) disease...
  40. ncbi Augmented production of transforming growth factor-beta by cultured peripheral blood mononuclear cells from patients with systemic sclerosis
    Minoru Hasegawa
    Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
    Arch Dermatol Res 296:89-93. 2004
    ..Thus, the enhanced production of TGF-beta by PBMC may contribute to the disease process in SSc..
  41. ncbi Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis
    Hidetaka Fujii
    Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
    J Dermatol Sci 35:43-51. 2004
    ..Although abnormalities of various chemokines are detected in systemic sclerosis (SSc), there are few findings concerning Th1 or Th2 chemoattractants...
  42. ncbi Prevalence of systemic sclerosis in a French multi-ethnic county
    V Le Guern
    Department of Internal Medicine, Hopital Avicenne, Assistance Publique Hopitaux de Paris, Bobigny, France
    Rheumatology (Oxford) 43:1129-37. 2004
    ..To assess the prevalence of systemic sclerosis (SSc) in a French multi-ethnic population and to examine ethnic differences...
  43. ncbi Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis
    L Ibba Manneschi
    Department of Anatomy, Histology and Forensic Medicine, University of Florence, Viale Morgagni, 85, 50134, Florence, Italy
    Rheumatology (Oxford) 44:607-13. 2005
    ..The aim was to study ultrastructural modifications of skin PNS fibres in SSc according to subsets [limited SSc (lSSc) and diffuse SSc (dSSc)] and phases (early and advanced) of the disease...
  44. ncbi Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases
    A Braun
    Department of Internal Medicine I Nephrology, University Hospital of Heidelberg, Germany
    Scand J Rheumatol 36:291-8. 2007
    ..To provide long-term follow-up data for anti-chromatin antibodies in lupus nephritis...
  45. ncbi Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases
    Manuel Ramos-Casals
    Department of Autoimmune Diseases, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, School of Medicine, University of Barcelona, Barcelona, Spain
    Semin Arthritis Rheum 35:312-21. 2006
    ..To analyze the clinical characteristics, follow-up, and fulfillment of classification criteria for other systemic autoimmune diseases (SAD) in patients with primary Sjögren syndrome (SS) and atypical autoantibodies...
  46. ncbi Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma
    Murat Colakoglu
    Departmen of Nephrology, School of Medicine, Pamukkale University, Denizli, Turkey
    Ann Pharmacother 41:1544-7. 2007
    ..To report the novel finding of a significant improvement in Raynaud's phenomenon symptoms with clonazepam in a patient with systemic sclerosis...
  47. ncbi Acrocyanosis from phenazopyridine-induced sulfhemoglobinemia mistaken for Raynaud phenomenon
    Tanaz A Kermani
    Division of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Rheumatol 15:127-9. 2009
    ..from chronic therapy with phenazopyridine was misdiagnosed as due to Raynaud phenomenon and limited scleroderma. This case illustrates the importance of taking into account medication-related adverse events when ..
  48. ncbi Treatment of systemic sclerosis
    V D Steen
    Department of Medicine, Georgetown University, Washington, DC, USA
    Am J Clin Dermatol 2:315-25. 2001
    ..b>Limited scleroderma patients have a prolonged duration of Raynaud's phenomenon and puffy fingers before they develop any skin ..
  49. ncbi The "sclerodermic hand": a radiological and clinical study
    Gian Luca Erre
    Cattedra di Reumatologia, University of Sassari, V le San Pietro 8, 07100 Sassari, Italy
    Joint Bone Spine 75:426-31. 2008
    ..To assess the clinical and radiographic features of hand involvement in patients with systemic sclerosis (SSc)...
  50. ncbi Association of HLA-DR5 (DR11) with systemic sclerosis (scleroderma) in Mexican patients
    G Vargas-Alarcon
    Department of Immunology and Rheumatology, Instituto Nacional de la Nutricion Salvador Zubiran, Mexico City, Mexico
    Clin Exp Rheumatol 13:11-6. 1995
    ..To study the association between Major Histocompatibility Complex (MHC) haplotypes and systemic sclerosis (SSc) in Mexican mestizo patients...
  51. pmc Risk of cancer in patients with scleroderma: a population based cohort study
    C L Hill
    Rheumatology Unit, The Queen Elizabeth Hospital, Woodville Rd, Woodville, South Australia 5011
    Ann Rheum Dis 62:728-31. 2003
    ..Previous studies have suggested an increased risk of cancer among patients with scleroderma...
  52. ncbi Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement
    Virginia Steen
    Georgetown University Medical Center, Division of Rheumatology, Immunology and Allergy, Department of Medicine, Gorman LL Building, 3800 Reservoir NW, Washington, DC 20007, USA
    Arthritis Rheum 48:516-22. 2003
    ..there are factors, such as the diffusing capacity for carbon monoxide (DLCO) or pulmonary artery pressure (PAP) on echocardiogram, that can predict the development of pulmonary hypertension (PHT) in patients with limited scleroderma.
  53. ncbi Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension
    D J Williamson
    Centre for Immunology, St Vincent s Hospital, Darlinghurst, USA
    Circulation 102:411-8. 2000
    ..This trial was designed to assess the hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with PHT, in which local overproduction of endothelin-1 (ET-1) is thought to play a pathogenic role...
  54. ncbi Association of clonally expanded T cells with the syndrome of primary biliary cirrhosis and limited scleroderma
    M J Mayo
    University of Texas Southwestern Medical Center at Dallas, Department of Internal Medicine, Dallas, TX, USA
    Hepatology 29:1635-42. 1999
    ..These clonal expansions provide evidence that stimulation of clonal populations of CD8(+) T cells is associated with the clinical syndrome of PBC with CREST...
  55. ncbi Daily occupations and well-being in women with limited cutaneous systemic sclerosis
    Gunnel Sandqvist
    Department of Clinical Neuroscience, Division of Occupational Therapy, Lund University, Lund SE 22100, Sweden
    Am J Occup Ther 59:390-7. 2005
    ..investigated occupational performance, well-being (operationalized as general life satisfaction, domain-specific life satisfaction, and self-rated health), and perceived symptoms in women with limited scleroderma and healthy controls.
  56. ncbi [Prevalence and clinical significance of cathepsin G antibodies in systemic sclerosis]
    P Grypiotis
    Cattedra e U O di Reumatologia, Universita degli Studi di Padova, Padova, Italia
    Reumatismo 55:256-62. 2003
    ..To evaluate the prevalence and clinical significance of cathepsin G antibodies in patients affected with systemic sclerosis (SSc, scleroderma)...
  57. ncbi Immunologic markers of systemic scleroderma in children
    M Błaszczyk
    Department of Dermatology, Warsaw School of Medicine, Poland
    Pediatr Dermatol 8:13-20. 1991
    ..The course of the disease was severe, and two children died. Four children with limited scleroderma had mild disease, and Scl-70 antibody, an immunologic marker that in adults is associated mostly with ..
  58. ncbi Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma
    H W Farber
    Pulmonary Center, Boston University School of Medicine, MA 02118, USA
    J Rheumatol 26:1195-6. 1999
    ..of acute epoprostenol infusion (pulmonary edema) in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology...
  59. ncbi Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension
    D J Williamson
    Centre for Immunology, St Vincent s Hospital, Darlinghurst, NSW, Australia
    Circulation 94:477-82. 1996
    ..Some patients with limited cutaneous systemic sclerosis develop isolated pulmonary hypertension with a similar clinical course. Therefore, we have measured the acute hemodynamic response to inhaled NO in such patients...
  60. ncbi Ciprofloxacin utility as antifibrotic in the skin of patients with scleroderma
    Enríquez Casillas Rubén
    Zone General Hospital, No 1, Mexican Institute for Social Security, University of Colima, Mexico
    J Dermatol 37:323-9. 2010
    ..double-blind randomized clinical trial, with placebo, was conducted on 32 patients with diffuse and limited scleroderma, who received oral ciprofloxacin (250 mg) or placebo every 12 h...
  61. ncbi Scleroderma renal crisis accompanied by new-onset pulmonary arterial hypertension: an acute systemic endothelial injury? Case report and literature
    Theodoros Dimitroulas
    Department of Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, St Kiriakidi 1, 54636, Thessaloniki, Greece
    Inflamm Allergy Drug Targets 9:313-8. 2010
    ..We report a case of a 41 year-old white woman with a 10 year-history of limited scleroderma, who developed the rare combination of Scleroderma Renal Crisis (SRC) and Systemic Sclerosis related ..
  62. ncbi [Systemic sclerosis - diagnosis and classification]
    E Genth
    Rheumaklinik und Rheumaforschungsinstitut Aachen, Burtscheider Markt 24, 52066, Aachen, Germany
    Z Rheumatol 65:268-74. 2006
    ..if disease expression is oligosymptomatic (undifferentiated), presenting with only Raynaud's phenomenon or limited scleroderma. Scleroderma specific antinuclear autoantibodies, which are present early and persistently in about 90% of ..
  63. ncbi Unilateral limited scleroderma-like changes following formation of an arteriovenous fistula
    Hugh Roberts
    Department of Dermatology, Alfred Hospital, Prahran, Victoria, Australia
    Australas J Dermatol 48:37-9. 2007
    ..Tissue hypoxia is believed to be a contributing factor in the pathogenesis of scleroderma, and this case demonstrates scleroderma-like changes in the setting of limb ischaemia...
  64. ncbi Autonomic nervous system and smooth muscle cell involvement in systemic sclerosis: ultrastructural study of 3 cases
    A Malandrini
    Institute of Neurological Sciences, University of Siena, Italy
    J Rheumatol 27:1203-6. 2000
    ..To investigate morphological abnormalities in nerve and smooth muscle structures of the anorectal wall underlying gastrointestinal dysfunction in patients with systemic sclerosis (SSc)...
  65. ncbi Exudative pleural effusion and pleural leukocytoclastic vasculitis in limited scleroderma
    Y H Lee
    Department of Internal Medicine, College of Medicine, Korea University, Seoul
    J Rheumatol 25:1006-8. 1998
    ..We describe a 43-year-old woman with limited scleroderma who developed an exudative pleural effusion associated with pleural leukocytoclastic vasculitis.
  66. ncbi Lack of association of a functionally relevant single nucleotide polymorphism of matrix metalloproteinase-1 promoter with systemic sclerosis (scleroderma)
    R W Johnson
    Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, The University of Texas Houston Medical School, Houston, TX 77030, USA
    Genes Immun 2:273-5. 2001
    ..between SSc patients and ethnically-matched controls, or between SSc patients with either diffuse or limited scleroderma. Furthermore, MMP-1 promoter genotypes did not significantly correlate with any of the major clinical ..
  67. ncbi Improved survival in limited scleroderma-related pulmonary artery hypertension
    Carlo Marini
    Fondazione Regione Toscana G Monasterio, Via G Moruzzi 1, Ghezzano, 56124, Pisa, Italy
    Intern Emerg Med 9:385-96. 2014
    ..3 (p < 0.001); for SvO2 <63.8 %, the HR was 3.7 (p < 0.01).NVD have beneficial effects in patients with SSc-PAH. Both DLco and SvO2 are predictors of survival and may assist in planning treatment. ..
  68. ncbi Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease
    David Launay
    Department of Internal Medicine, National Center for Vascular Manifestations of Scleroderma, Regional University Hospital Claude Huriez Hospital, Lille, France
    J Rheumatol 34:1005-11. 2007
    ..To determine the prevalence and characteristics of moderate to severe pulmonary hypertension (PH) in patients with systemic sclerosis (SSc) with and without interstitial lung disease (ILD)...
  69. ncbi Natural remedies for scleroderma
    Alan R Gaby
    Altern Med Rev 11:188-95. 2006
    ..This article reviews several promising natural treatments for scleroderma, including para-aminobenzoic acid, vitamin E, vitamin D, evening primrose oil, estriol, N-acetylcysteine, bromelain, and an avocado/soybean extract...
  70. ncbi Juvenile onset systemic sclerosis: a single center experience of 23 cases from Asia
    Ramnath Misra
    Department of Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, 226014, India
    Clin Rheumatol 26:1259-62. 2007
    ..2-26 years). Among these, 14 had diffuse systemic sclerosis (DSSc), while 9 had limited scleroderma (LSSc)...
  71. pmc The cytoplasmic linker protein CLIP-170 is a human autoantigen
    K J Griffith
    Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Clin Exp Immunol 127:533-8. 2002
    ..The clinical diagnoses in these patients were limited scleroderma, glioblastoma and idiopathic pleural effusion...
  72. ncbi A case of limited systemic sclerosis with p-ANCA, complicated by multiple cerebral hemorrhages
    Bharath Manu Akkara Veetil
    Pennsylvania Hospital, Philadelphia, PA, 19107, USA
    Rheumatol Int 29:325-9. 2009
    ....
  73. ncbi [Gastrointestinal involvement in systemic sclerosis]
    Isabelle Marie
    Departement de Medecine Interne, Inserm 644, Centre Hospitalier Universitaire, Rouen
    Presse Med 35:1952-65. 2006
    ..Anorectal involvement is frequent in SSc patients (50-70%) and causes fecal incontinence and rectal prolapse. Other digestive manifestations, including liver impairment, are less common in SSc...
  74. ncbi Increased serum fractalkine in systemic sclerosis. Down-regulation by prostaglandin E1
    J Sicinska
    Department of Dermatology, CSK MSWiA, Warsaw, Poland
    Clin Exp Rheumatol 26:527-33. 2008
    ....
  75. ncbi Effects of olopatadine in limited scleroderma with peripheral eosinophils
    Motoo Kikuchi
    Department of Medicine, Nanakuri Sanatorium, Fujita Health University, Tsu City, Japan
    Geriatr Gerontol Int 8:204-8. 2008
    ..We investigated the effect of olopatadine hydrochloride in a series of cases of limited scleroderma (LS)...
  76. ncbi Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement
    L Beretta
    Unit of Immunology, IRCCS Maggiore Policlinico Hospital, University of Milan, Milan, Italy
    Scand J Rheumatol 35:468-71. 2006
    ..Accordingly, it has been hypothesized that HRT might help to prevent the development of iPHT...
  77. ncbi Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis
    Yasuhito Hamaguchi
    Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
    J Rheumatol 35:2363-71. 2008
    ..To examine serum concentrations of insulin-like growth factor (IGF-1) and IGF binding protein (IGFBP-3), a major carrier protein for IGF-1, in patients with systemic sclerosis (SSc); and to relate the results to clinical features in SSc...
  78. ncbi Necrotising scleritis and connective tissue disease--three cases and a review
    Sharmin Nizam
    Academic Unit of Musculoskeletal Medicine, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Chapeltown Road, Leeds LS74SA, UK
    Clin Rheumatol 28:339-41. 2009
    ..to be associated with connective tissue disease but has not previously been reported in association with limited scleroderma. It is often a difficult condition to treat and without adequate early intervention leads to significant ..
  79. ncbi Autoantibodies in systemic sclerosis
    Virginia D Steen
    Department of Medicine, Georgetown University, Washington, DC 2007, USA
    Semin Arthritis Rheum 35:35-42. 2005
    ..To describe the clinical, laboratory, and prognostic features associated with the scleroderma-specific autoantibodies...
  80. ncbi Pregnancy in scleroderma
    Virginia D Steen
    Department of Medicine, Georgetown University Medical Center, Washington, DC 20007, USA
    Rheum Dis Clin North Am 33:345-58, vii. 2007
    ..All patients who become pregnant during this high-risk time should be monitored extremely carefully, particularly for renal crisis...
  81. ncbi Morphologic and histochemical changes in the skin of patients with scleroderma
    Gabriela Ieremia
    Department of Rheumatology, County Hospital Baia Mare, Romania
    Rom J Morphol Embryol 48:361-7. 2007
    ..The purpose of the present work was to evaluate the histochemical aspects of sclerodermic skin, obtained through biopsy of the typical lesions from the forearm skin...
  82. ncbi HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities
    M Bellia
    Dipartimento di Biotecnologie e Medicina Legale, Sezione di Scienze Radiologiche, Universita di Palermo, Palermo, Italy
    Radiol Med 114:190-203. 2009
    ..In addition, we propose the use of high resolution computed tomography (HRCT) indices of alveolitis and fibrosis to discriminate between different stages of the disease...
  83. ncbi Avascular areas on nailfold capillary microscopy of patients with Wegener's granulomatosis
    H J Anders
    Division of Rheumatology, Medizinische Poliklinik, Klinikum Innenstadt, Ludwig Maximilians University, Munich, Germany
    Clin Rheumatol 19:86-8. 2000
    ..findings from 116 patients selected for NCM by one of the following indications: (1) suspected diffuse or limited scleroderma or dermatomyositis, (2) evaluation of Raynaud's phenomenon (RP) or (3) suspected small-vessel vasculitis...
  84. ncbi Association of 5'-untranslated region of the Fibrillin-1 gene with Japanese scleroderma
    Takao Kodera
    Department of Microbiology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Gene 297:61-7. 2002
    ..In particular, a high frequency of anti-Fibrillin-1 was observed in Japanese patients with diffuse and limited scleroderma or CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia) syndrome...
  85. ncbi [Classification criteria of scleroderma]
    Jean Cabane
    Service de Medecine Interne, Hopital Saint Antoine, Paris
    Presse Med 35:1916-22. 2006
    ..The old term "CREST" tends to be abandoned due to its lack of specificity...
  86. pmc Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients
    Bozena Dziankowska-Bartkowiak
    Division of Immunodermatology, Medical University of Lodz, Poland
    Mediators Inflamm 2005:144-9. 2005
    ..The study group comprised 34 patients (19 with limited scleroderma (lSSc) and 15 with diffuse scleroderma (dSSc))...
  87. ncbi Association of limited scleroderma and pulmonary hypertension in a patient with primary biliary cirrhosis
    Yasumi Katsuta
    First Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
    J Nippon Med Sch 72:230-5. 2005
    We report a male patient with primary biliary cirrhosis (PBC) who developed limited scleroderma (l-SSc) and pulmonary hypertension (PHT). He had noticed shortness of breath seven months earlier, which slowly progressed before admission...
  88. ncbi Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis
    Masanari Kodera
    Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
    Arthritis Rheum 52:2889-96. 2005
    ....
  89. ncbi Relaxin receptors--new drug targets for multiple disease states
    E T van der Westhuizen
    Department of Pharmacology, Monash University, Wellington Road, Clayton, Victoria 3800, Australia
    Curr Drug Targets 8:91-104. 2007
    ..The focus of this review is to bring together recent developments in the relaxin receptor field and to highlight their potential as drug targets...
  90. ncbi Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B)
    Amélie Servettaz
    Universite Paris Descartes, Faculte de Medecine, UPRES EA 1833, Laboratoire d Immunologie, Paris, France
    Clin Immunol 120:212-9. 2006
    ..The main target of anti-endothelial cell antibodies in patients with limited cutaneous SSc is the nuclear and ubiquitous protein CENP-B...
  91. ncbi Factors related to oral hygiene in persons with scleroderma
    J L Poole
    Occupational Therapy Graduate Program, Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131 0001, USA
    Int J Dent Hyg 3:13-7. 2005
    ..The purpose of this study was to assess potential risk factors for the development of poor oral hygiene and increased dental caries in individuals with scleroderma...
  92. ncbi Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score
    M Dziadzio
    Centre for Rheumatology, Royal Free and University College Medical School, University College London, London NW3 2PF, UK
    Rheumatology (Oxford) 44:1518-24. 2005
    ..To determine the relationship between clinical features and circulating levels of active transforming growth factor (TGF) beta1 in the major subsets of systemic sclerosis (SSc)...
  93. pmc Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation
    Michele L Donato
    Department of Blood and Bone Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Blood 107:463-6. 2006
    ..High-dose melphalan followed by autologous transplantation appears effective for improving the symptoms and systemic manifestations of scleromyxedema...
  94. ncbi Ultrasound elastography assessment of skin involvement in systemic sclerosis: lights and shadows
    Annamaria Iagnocco
    Rheumatology Unit, Department of Clinical and Medical Therapy, Sapienza University of Rome, Rome, Italy
    J Rheumatol 37:1688-91. 2010
    ..To assess skin elasticity in systemic sclerosis (SSc) by using a new imaging modality, ultrasound elastography (UE)...
  95. ncbi [Pulmonary veno-occlusive disease in a patient with scleroderma and the CREST syndrome]
    Arne K Andreassen
    Hjertemedisinsk avdeling, Rikshospitalet, Oslo
    Tidsskr Nor Laegeforen 123:3391-2. 2003
    ..Pulmonary veno-occlusive disease is a rare and poorly understood condition that affects the postcapillary pulmonary vasculature, posing diagnostic problems and treatment dilemmas...
  96. ncbi HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women
    L S Loubière
    Immunogenetics Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Rheumatology (Oxford) 44:318-22. 2005
    ..We investigated HLA class II alleles in women with systemic sclerosis (SSc), a rare disease that preferentially affects women...
  97. ncbi Recurrent pericardial effusion and pericardial tamponade in a patient with limited systemic sclerosis
    S Nabatian
    Cardiology Fellow Lutheran General Hospital, Park Ridge, IL 60068, USA
    Rheumatol Int 27:759-61. 2007
    ..Previously reported large pericardial effusions have been seen in patients with pulmonary hypertension and renal failure however these were absent in our patient...
  98. ncbi Scleroderma in Australian aborigines
    J Zurauskas
    Department of Medicine, Allergy and Arthritis, Flinders Medical Centre, Bedford Park, South Australia, Australia
    Intern Med J 35:60-2. 2005
    ..scleroderma does occur in indigenous Australians but further studies are needed to confirm the apparent infrequency of centromere-associated limited scleroderma (which is the commonest form of scleroderma in our Caucasian population).
  99. ncbi Clinical differences between idiopathic and scleroderma-related pulmonary hypertension
    Micah R Fisher
    Emory University, Atlanta, Georgia, USA
    Arthritis Rheum 54:3043-50. 2006
    ..This study tested the hypothesis that an increased prevalence of left heart disease might explain the higher mortality in patients with PAH-Scl compared with patients with IPAH...
  100. ncbi Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis
    Predrag Ostojic
    Clinical Rheumatology III, Institute of Rheumatology, School of Medicine, University of Belgrade, Belgrade, Yugoslavia
    Clin Rheumatol 25:453-7. 2006
    ..Fingertip osteolysis, telangiectasia, and arthritis are equally frequent in both forms of the disease...
  101. ncbi The efficacy of self-administered stretching for finger joint motion in Japanese patients with systemic sclerosis
    Naoki Mugii
    Department of Dermatology and Division of Rehabilitation Science, Kanazawa University Hospital, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan
    J Rheumatol 33:1586-92. 2006
    ..To determine the efficacy of self-administered stretching of each finger in Japanese patients with systemic sclerosis (SSc)...

Research Grants2

  1. Cardiopulmonary Exercise Testing: Pulmonary Hypertension
    Ronald Oudiz; Fiscal Year: 2007
    .._l.Center. PHS 398/2590(Rev.05/01) Page _, LJ ContinuationFormatPage NumberpagesconsecutivelyatthebottomthroughoutheapplicationD. o no_u_stesuffixesuchas3a, 3b. ..
  2. Alveolitis and Fibrosis in Scleroderma Lung Disease
    Jonathan Goldin; Fiscal Year: 2004
    ..These findings will potentially improve our understanding of the relationship between alveolitis and fibrosis and to the pathogenesis of fibrosis in SLD. ..